Stem cell mobilization in multiple myeloma patients relapsing after previous autologous hematopoietic stem cell transplantation: A multicenter report by the Polish Myeloma Study Group.

Joanna Drozd-Sokołowska Anna Waszczuk-GajdaMagdalena TopczewskaJoanna MańkoIwona HusAnna Szmigielska-KapłonMateusz NowickiIwona Grygoruk-WiśniowskaMałgorzata Krawczyk-KuliśJoanna Romejko-JarosińskaEwa FrączakTomasz WróbelBeata Piątkowska-JakubasKrzysztof MądryPiotr BoguradzkiMałgorzata KrólMagdalena KoziołMarek HusAnna KopińskaAnna DmoszyńskaGrzegorz Władysław BasakJadwiga Dwilewicz-Trojaczek

Published in: Journal of clinical apheresis (2021)

Remobilization after previous autoHSCT is feasible only in a proportion of patients. Cytarabine is associated with the highest rate of successful mobilization and the highest yield of mobilized CD34+ cells. The toxicity requires careful surveillance of these patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
stem cells
chronic kidney disease
prognostic factors
peritoneal dialysis
acute myeloid leukemia
multiple myeloma
multiple sclerosis
public health
rheumatoid arthritis
oxidative stress
cell death
bone marrow
peripheral blood
low dose
platelet rich plasma